Tailored Rituxan Treatment Offers No Added Benefit in Relapse Rates to AAV Patients, Phase 3 Trial Finds – ANCA Vasculitis News

Tailored Rituxan Treatment Offers No Added Benefit in Relapse Rates to AAV Patients, Phase 3 Trial Finds – ANCA Vasculitis News

Tailored Rituxan Treatment Offers No Added Benefit in Relapse Rates to AAV Patients, Phase 3 Trial Finds – ANCA Vasculitis News
Published on 2017-12-04